All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Jeffrey Lancet, Moffitt Cancer Center, Tampa, US. We asked: What are the most important and recent advances made in AML treatment?
Jeffrey Lancet discusses the emergence of novel compounds and how that has shaped the AML treatment landscape. He summarizes the results of his study that examine a new regimen in a high-risk patient population. Jeffrey Lancet concludes by discussing a study that explored new maintenance therapies that aimed to prolong remission.
What are the most important and recent advances made in AML treatment?
Editorial theme | Novel combination therapies using targeted agents
This article provides a summary of content relating to novel agent-containing combinations to date & introduces the new editorial theme of ‘Novel combination therapies using...
Using cusatuzumab to target CD70 has shown to eliminate acute myeloid leukemia stem cells in humans
Summary of an open-label, non-randomized phase I/II study study evaluating whether treatment with HMAs can be improved by the addition of the...
Subscribe to get the best content related to AML delivered to your inbox